Jun Horiguchi
Overview
Explore the profile of Jun Horiguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
266
Citations
3052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Narui K, Miura D, Hasegawa Y, Tachibana A, Horiguchi J, Hayashi M, et al.
Clin Breast Cancer
. 2022 Sep;
22(8):e881-e891.
PMID: 36151017
Objective: Neoadjuvant chemotherapy (NAC) is essential for surgical downstaging of early-stage breast cancer, but taxane administration is associated with neuropathy. We investigated whether eribulin induces less neuropathy than paclitaxel. Methods:...
12.
Horiguchi J, Watanabe K, Kondo K, Iwatake A, Sakamoto H, Susuta Y, et al.
Psychiatry Clin Neurosci
. 2022 Sep;
76(11):560-569.
PMID: 36114799
Aim: Valbenazine is approved in the US for treatment of tardive dyskinesia (TD); however, efficacy/safety data in Asian populations are lacking. We assessed the efficacy/safety of valbenazine in Japanese patients....
13.
Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, et al.
J Bone Miner Metab
. 2022 Aug;
40(6):998-1006.
PMID: 36042056
Introduction: β-ray strontium-89 (Sr-89) intra-irradiation therapy has been approved and clinically used to reduce bone metastasis pain not alleviated by bone-modifying agents, external radiation, and analgesic agents. We examined the...
14.
Kurozumi S, Kaira K, Matsumoto H, Kurosumi M, Yokobori T, Kanai Y, et al.
Sci Rep
. 2022 Feb;
12(1):2742.
PMID: 35177712
L-type amino acid transporter 1 (LAT1), also referred to as SLC7A5, is believed to regulate tumor metabolism and be associated with tumor proliferation. In invasive breast cancer, we clinicopathologically investigated...
15.
Kurozumi S, Katayama A, Shirabe K, Horiguchi J, Rakha E
Oncotarget
. 2021 Nov;
12(22):2302-2304.
PMID: 34733421
No abstract available.
16.
Honda C, Kurozumi S, Katayama A, Hanna-Khalil B, Masuda K, Nakazawa Y, et al.
Mol Clin Oncol
. 2021 Oct;
15(6):252.
PMID: 34671471
Tumor-infiltrating lymphocytes (TILs) are a significant prognostic factor in triple-negative breast cancer. However, the clinicopathological significance of TILs in estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative...
17.
Wake R, Araki T, Fukushima M, Matsuda H, Inagaki T, Hayashida M, et al.
Early Interv Psychiatry
. 2021 May;
16(3):272-280.
PMID: 33966347
Background: Early diagnosis of individuals' at-risk mental state (ARMS) is important for preventing their pathogenesis or, at least, delaying onset of overt psychosis. Traditional diagnosis of ARMS subjects is mainly...
18.
Miyaoka T, Wake R, Araki T, Inoue K, Horiguchi J
Asian J Psychiatr
. 2021 May;
60:102662.
PMID: 33962269
No abstract available.
19.
Yanai K, Fujii T, Horiguchi J, Nakazawa Y, Kurozumi S, Obayashi S, et al.
BMC Cancer
. 2020 Nov;
20(1):1068.
PMID: 33158432
Background: S-1 and cyclophosphamide (CPA) can be given orally, and their combination may have great potential for treating metastatic breast cancer (MBC). A phase I study of sequential S-1 and...
20.
Ogino M, Fujii T, Nakazawa Y, Higuchi T, Koibuchi Y, Oyama T, et al.
In Vivo
. 2020 Nov;
34(6):3483-3487.
PMID: 33144457
Background/aim: We evaluated the usefulness of topoisomerases (TOPs) expression as prognostic predictors in breast cancer. Patients And Methods: We retrospectively investigated sixty cases with primary breast cancer. We evaluated the...